Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Asymmetric Reduction . These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN107118144A details a safer NaBH4-I2 reduction for ezetimibe intermediates, offering high purity and cost reduction in pharmaceutical manufacturing.
Advanced asymmetric synthesis of pyrrolidine carboxylic acids offers high purity and yield. Optimize your supply chain for metabolic disease drug intermediates with scalable processes.
Patent CN102643757B reveals a novel biocatalytic route for statin intermediates. Discover cost reduction and supply chain advantages for pharmaceutical manufacturing.
Patent CN104513187A details a high-purity Ezetimibe synthesis route. This method offers significant cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN103421854A reveals a green enzymatic route for Duloxetine intermediates, offering high purity and reduced solvent waste for pharmaceutical supply chains.
Novel biocatalytic synthesis ensures high optical purity for alpha-lipoic acid production. Cost-effective and scalable pharmaceutical intermediate manufacturing solution.
Patent CN1051087C reveals a safer in-situ method for chiral reduction. Achieve high optical purity alcohols with reduced costs and simplified supply chains for API manufacturing.
Patent CN111686809A reveals a robust dual-enzyme system for producing chiral statin intermediates, offering enhanced stability and cost-effective manufacturing solutions.
Patent CN110387359A enables high-purity statin intermediate production via engineered carbonyl reductase mutants ensuring supply chain stability.
Patent CN103755748A reveals a high-yield route for chiral ferrocene ligands. Discover cost reduction and supply chain advantages for pharmaceutical manufacturing.
Patent CN106497996B reveals a high-ee enzymatic route for chiral alcohols. Discover cost reduction in pharmaceutical intermediates manufacturing and supply chain advantages.
Novel catalytic method for Dextromethorphan HBr. High purity, cost-effective manufacturing. Reliable supply chain for pharmaceutical intermediates.
Novel 5-step route for Ozanimod intermediates reduces cost and improves safety. Ideal for API intermediates manufacturing and supply chain optimization.
Patent CN105316250B reveals Empedobacter brevis ZJUY-1401 for high-purity chiral alcohol synthesis. Offers significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Novel biocatalytic route for chiral pyrrolidine intermediates. High yield, mild conditions, cost-effective supply for Trk inhibitor manufacturing.
Novel iron catalyst method for Rimegepant intermediates reduces cost and avoids precious metals ensuring supply chain stability and high purity for global pharmaceutical manufacturing partners.
Discover a cost-effective synthesis route for homophenylalanine derivatives via Michael addition and reduction, offering high purity and scalable manufacturing for pharmaceutical intermediates.
Patent CN1254760A reveals microbial route for Actinol. Enhances supply chain reliability and cost reduction in carotenoid intermediate manufacturing significantly.
Novel synthesis route for PI3K inhibitor intermediates ensures high purity and scalable production for global pharmaceutical supply chains and cost efficiency in manufacturing.
Patent CN112481226A discloses solvent-tolerant ADH mutants enabling 99.9% conversion for chiral diaryl alcohols, offering a green alternative to costly chemical synthesis.